Javascript must be enabled to continue!
Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides
View through CrossRef
ABSTRACT
The
N
‐formyl peptide receptors (FPRs) are a family of G‐protein coupled receptors that re‐spond to proinflammatory
N
‐formylated bacterial peptides
(e.g.
, formyl‐Met‐Leu‐Phe, fMLF) and, thus, contribute to the host response to bacterial infection. Paradoxically, a growing body of evidence suggests that some members of this receptor family may also be targets for certain anti‐inflammatory molecules, including annexin Al (ANXA1), which is an important mediator of glucocorticoid (GC) action. To explore further the potential role of FPRs in mediating ANXA1 actions, we have focused on the pituitary gland, where ANXA1 has a well‐defined role as a cell‐cell mediator of the inhibitory effects of GCs on the secretion of cortico‐trophin (ACTH), and used molecular, genetic, and pharmacological approaches to address the question in well‐established rodent models. Reverse transcriptase‐polymerase chain reaction (RT‐PCR) analysis identified mRNAs for four FPR family members in the mouse anterior pituitary gland, Fpr‐rsl, Fpr‐rs2, Fpr‐rs6, and Fpr‐rs7. Functional studies confirmed that, like dexa‐methasone, ANXA1 and two ANXAl‐derived peptides (ANXA1
1
_
188
and ANXA1
Ac2
_
26
) inhibit the evoked release of ACTH from rodent anterior pituitary tissue
in vitro.
Fpr1 gene deletion failed to modify the pituitary responses to dexamethasone or ANXA1
Ac2_26
. However, lipoxin A4 (LXA4, 0.02–2μM, a lipid mediator with high affinity for Fpr‐rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1–100 μM) but not lower (10–100 nM) concentrations. Additionally, a nonselective FPR antagonist (Boc1, 100 μM) overcame the effects of dexametha‐sone, ANXA1
1
_
188
, ANXA1
Ac2
_
26
, fMLF, and LXA4 on ACTH release, although at a lower concentration (50 μM), it was without effect. Together, the results suggest that the actions of ANXA1 in the pituitary gland are independent of Fpr1 but may involve other FPR family members, in particular, Fpr‐rs1 or a closely related receptor. They thus provide the first evidence for a role of the FPR family in the regulation of neuroendocrine function.—John, C. D., Sahni, V., Mehet, D., Morris, J. F., Christian, H. C., Perretti, M., Flower, R. J., Solito E., Buckingham J. C. Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides.
FASEB J.
21, 1037–1046 (2007)
Title: Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides
Description:
ABSTRACT
The
N
‐formyl peptide receptors (FPRs) are a family of G‐protein coupled receptors that re‐spond to proinflammatory
N
‐formylated bacterial peptides
(e.
g.
, formyl‐Met‐Leu‐Phe, fMLF) and, thus, contribute to the host response to bacterial infection.
Paradoxically, a growing body of evidence suggests that some members of this receptor family may also be targets for certain anti‐inflammatory molecules, including annexin Al (ANXA1), which is an important mediator of glucocorticoid (GC) action.
To explore further the potential role of FPRs in mediating ANXA1 actions, we have focused on the pituitary gland, where ANXA1 has a well‐defined role as a cell‐cell mediator of the inhibitory effects of GCs on the secretion of cortico‐trophin (ACTH), and used molecular, genetic, and pharmacological approaches to address the question in well‐established rodent models.
Reverse transcriptase‐polymerase chain reaction (RT‐PCR) analysis identified mRNAs for four FPR family members in the mouse anterior pituitary gland, Fpr‐rsl, Fpr‐rs2, Fpr‐rs6, and Fpr‐rs7.
Functional studies confirmed that, like dexa‐methasone, ANXA1 and two ANXAl‐derived peptides (ANXA1
1
_
188
and ANXA1
Ac2
_
26
) inhibit the evoked release of ACTH from rodent anterior pituitary tissue
in vitro.
Fpr1 gene deletion failed to modify the pituitary responses to dexamethasone or ANXA1
Ac2_26
.
However, lipoxin A4 (LXA4, 0.
02–2μM, a lipid mediator with high affinity for Fpr‐rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1–100 μM) but not lower (10–100 nM) concentrations.
Additionally, a nonselective FPR antagonist (Boc1, 100 μM) overcame the effects of dexametha‐sone, ANXA1
1
_
188
, ANXA1
Ac2
_
26
, fMLF, and LXA4 on ACTH release, although at a lower concentration (50 μM), it was without effect.
Together, the results suggest that the actions of ANXA1 in the pituitary gland are independent of Fpr1 but may involve other FPR family members, in particular, Fpr‐rs1 or a closely related receptor.
They thus provide the first evidence for a role of the FPR family in the regulation of neuroendocrine function.
—John, C.
D.
, Sahni, V.
, Mehet, D.
, Morris, J.
F.
, Christian, H.
C.
, Perretti, M.
, Flower, R.
J.
, Solito E.
, Buckingham J.
C.
Formyl peptide receptors and the regulation of ACTH secretion: targets for annexin A1, lipoxins, and bacterial peptides.
FASEB J.
21, 1037–1046 (2007).
Related Results
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see
Rapid Communications in Mass Spectrometry
2012,
26
, ...
EP1265 - ECE_2329 - When the source remains hidden-diagnostic dilemmas in ACTH-dependent Cushing's syndrome
EP1265 - ECE_2329 - When the source remains hidden-diagnostic dilemmas in ACTH-dependent Cushing's syndrome
Abstract
Aim
To analyze the diagnostic challenges in ACTH-dependent Cushing's syndrome when no causative lesion is initia...
8738 Unveiling Potential Therapeutic Candidates for ACTH-Silent Pituitary Neuroendocrine Tumors Through High Throughput Drug Screening
8738 Unveiling Potential Therapeutic Candidates for ACTH-Silent Pituitary Neuroendocrine Tumors Through High Throughput Drug Screening
Abstract
Disclosure: J.M. Marques: None. N.D. D' Alessandre: None. G.D. Guardia: None. F.L. Craveiro: None. C. Grutzmacher: None. G.O. Silva: None. B.B. Mendonca: No...
Activation of Endothelial Cells by β2-Glycoprotein I (β2GPI) Antibodies Is Mediated by Annexin II Cross Linking and May Involve TLR4.
Activation of Endothelial Cells by β2-Glycoprotein I (β2GPI) Antibodies Is Mediated by Annexin II Cross Linking and May Involve TLR4.
Abstract
The antiphospholipid antibody syndrome (APS) is characterized by the presence of circulating antiphospholipid antibodies (APLA) in association with thrombos...
Photoaffinity labeling of corticotropin receptors.
Photoaffinity labeling of corticotropin receptors.
A photoaffinity label for corticotropin (ACTH) receptors was prepared by selective chemical modification of the single tryptophan residue in the hormone by reaction with 2-nitro-5-...
Adrenocorticotropin Receptor and Adrenal Disorders
Adrenocorticotropin Receptor and Adrenal Disorders
The ACTH receptor is the shortest G-protein-coupled receptor to date and consists of 297 residues with two putative glycosylation sites at the extracellular N terminus. In vitro st...
Pulsatile secretion of α-MSH and the differential effects of dexamethasone and haloperidol on the secretion of α-MSH and ACTH in dogs
Pulsatile secretion of α-MSH and the differential effects of dexamethasone and haloperidol on the secretion of α-MSH and ACTH in dogs
Abstract
This study was performed to determine whether, in the dog, there is at any time pulsatile release of α-MSH and whether secretion of ACTH from the pars in...
Annexin A1 conveys neuroprotective function via inhibiting oxidative stress in diffuse axonal injury of rats
Annexin A1 conveys neuroprotective function via inhibiting oxidative stress in diffuse axonal injury of rats
Abstract
Purpose
Diffuse axonal injury (DAI) is a critical pathological facet of traumatic brain injury (TBI). Oxidative stress plays a significant role in progress of DAI...

